Guardant Health (NASDAQ:GH) Insider Sells $3,241,757.64 in Stock

Guardant Health, Inc. (NASDAQ:GH) insider Chris Freeman sold 31,452 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.07, for a total value of $3,241,757.64. Following the sale, the insider directly owned 25,987 shares of the company’s stock, valued at approximately $2,678,480.09. This represents a 54.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Guardant Health Trading Down 0.6%

Shares of GH opened at $102.62 on Thursday. The business’s 50-day moving average price is $87.13 and its 200 day moving average price is $64.63. The stock has a market capitalization of $12.93 billion, a P/E ratio of -31.97 and a beta of 1.58. Guardant Health, Inc. has a 1-year low of $29.91 and a 1-year high of $112.43.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. The firm’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.88) EPS. On average, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Evercore ISI raised their target price on Guardant Health from $68.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Stifel Nicolaus set a $73.00 price target on Guardant Health in a report on Thursday, September 25th. JPMorgan Chase & Co. increased their price objective on Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Finally, Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Thursday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $80.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers purchased a new stake in shares of Guardant Health during the 1st quarter worth about $211,000. Natixis Advisors LLC acquired a new position in Guardant Health in the first quarter worth approximately $984,000. PNC Financial Services Group Inc. raised its position in Guardant Health by 25.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock valued at $112,000 after acquiring an additional 537 shares in the last quarter. Invesco Ltd. lifted its stake in Guardant Health by 100.9% in the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after acquiring an additional 1,403,670 shares during the last quarter. Finally, Aigen Investment Management LP grew its position in Guardant Health by 9.0% in the first quarter. Aigen Investment Management LP now owns 28,298 shares of the company’s stock worth $1,205,000 after acquiring an additional 2,341 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.